EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival

Pablo Romero-Morelos iD, Ana Lilia González-Yebra iD, Anaid Herrerías-García, Francisco Arath Ruíz-Velázquez, Luis Jonathan Bueno-Rosario, Beatríz González-Yebra iD

Genes · 2024

DOI: 10.3390/genes15050567 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Pablo Romero-Morelos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Investigación, Universidad Estatal del Valle de Ecatepec, Ecatepec 55210, Estado de México, Mexico. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the presence of the Philadelphia chromosome, a product of the reciprocal translocation t(9;22)(q34;q11), in the BCR and ABL genes. These rearrangements in both genes lead to the formation of various fusion mRNA products, with preferential expression of b2a2, b3a2, and other BCR::ABL1 mRNA variants, combined with additional chromosomal abnormalities. Notably, the distribution and frequency of different mRNA variants vary in different populations. However, studies concerning this in Mexico are limited, and the results have been inconclusive. This study therefore aimed to determine the distribution of BCR::ABL1 mRNA variants in different clinical phases of CML and their effect on hematological parameters and patient survival. This study included 33 patients, whose demographic, clinical, and molecular data on BCR::ABL1 mRNA variants and hematological parameters were collected to identify potential associations. A total of 84.8% (n = 28) of patients had BCR::ABL1 translocation and increased platelet and basophil counts. The most frequent mRNA variant was b3a2 (64.3%), followed by b2a2 (28.6%) and e1a2 (3.6%). Concerning the clinical phases of CML, 75.8% (n = 25), 21.2% (n = 7), and 3% (n = 1) of patients were in the chronic, blast, and accelerated phases, respectively. Moreover, the b3a2 mRNA variant was more commonly identified in patients in the chronic phase. No correlation was observed between mRNA variant expression and patient survival. However, b2a2 was indicative of patients with longer survival as well as those treated with imatinib or nilotinib. Additionally, platelet count could be a marker of BCR::ABL1 translocation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveFusion Proteins, bcr-ablHumansFemaleMaleMiddle AgedAdultAgedRNA, MessengerImatinib MesylateTranslocation, GeneticYoung Adult

Stichwörter der Autor:innen

Philadelphia chromosomeb2a2b3a2chronic myeloid leukemiae1a2survival

Substanzen

Fusion Proteins, bcr-ablRNA, MessengerBCR-ABL1 fusion protein, humanImatinib Mesylate

Autor:innen und Institutionen

  • Departamento de Investigación, Universidad Estatal del Valle de Ecatepec, Ecatepec 55210, Estado de México, Mexico.
  • Departamento de Ciencias Aplicadas al Trabajo, División Ciencias de la Salud, Universidad de Guanajuato, Campus León, León 37670, Guanajuato, Mexico.
  • Departamento de Medicina y Nutrición, División Ciencias de la Salud, Universidad de Guanajuato, Campus León, León 37670, Guanajuato, México.
  • Unidad de Investigación, Hospital Regional de Alta Especialidad del Bajío, Servicios de Salud del Instituto Mexicano del Seguro Social para el Bienestar (IMSS-BIENESTAR), León 37544, Guanajuato, Mexico.

ORCID-Profile: Pablo Romero-Morelos, Ana Lilia González-Yebra, Beatríz González-Yebra

Zitieren

APA

Romero-Morelos, P., González-Yebra, A. L., Herrerías-García, A., Ruíz-Velázquez, F. A., Bueno-Rosario, L. J., & González-Yebra, B. (2024). Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival. Genes. https://doi.org/10.3390/genes15050567

Vancouver

Romero-Morelos P, González-Yebra AL, Herrerías-García A, Ruíz-Velázquez FA, Bueno-Rosario LJ, González-Yebra B. Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival. Genes. 2024. doi:10.3390/genes15050567

BibTeX
@article{RomeroMorelos2024,
  author = {Romero-Morelos, Pablo and González-Yebra, Ana Lilia and Herrerías-García, Anaid and Ruíz-Velázquez, Francisco Arath and Bueno-Rosario, Luis Jonathan and González-Yebra, Beatríz},
  title = {Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival},
  journal = {Genes},
  year = {2024},
  doi = {10.3390/genes15050567}
}
Kostenlos starten →